WordNet

a severe recurring vascular headache; occurs more frequently in women than men (同)megrim, sick_headache, hemicrania
tracing descent from either the paternal or the maternal line only
involving only one part or side; "unilateral paralysis"; "a unilateral decision" (同)one-sided
pain in the head caused by dilation of cerebral arteries or muscle contractions or a reaction to drugs (同)head ache, cephalalgia

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における頭痛の評価 evaluation of headache in adults
2. 片頭痛以外の頭痛症候群 headache syndromes other than migraine
3. 群発頭痛：疫学、臨床的特徴、および診断 cluster headache epidemiology clinical features and diagnosis
4. 頭痛を訴える小児へのアプローチ approach to the child with headache
5. 新規発症持続性連日性頭痛 new daily persistent headache

Changes in Clinical Management and Diagnosis following DaTscan™ SPECT Imaging in Patients with Clinically Uncertain Parkinsonian Syndromes: A 12-Week Follow-Up Study.

Kupsch A, Bajaj N, Weiland F, Tartaglione A, Klutmann S, Copp R, Sherwin P, Tate A, Grachev ID.SourceDepartment of Neurology, Charité Campus Virchow-Kinikum, University Medicine Berlin, Berlin, Germany.
Neuro-degenerative diseases.Neurodegener Dis.2013;11(1):22-32. Epub 2012 May 8.
Background: An accurate diagnosis is important for timely and adequate treatment in patients with clinically uncertain parkinsonian syndrome (CUPS). Objective: The objective of this study was to assess safety and changes in clinical management, diagnosis and quality of life (QoL) at 4 and 12 weeks f
PMID 22571977

Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A.

Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, Sato H, Kuroi T, Ebine T, Koizumi K, Suzuki N.SourceDepartment of Neurology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. Electronic address: shimizu-toshi@umin.ac.jp.
Neurobiology of disease.Neurobiol Dis.2012 Dec;48(3):367-78. doi: 10.1016/j.nbd.2012.07.010. Epub 2012 Jul 20.
Botulinum neurotoxin type-A (BoNT-A) is clinically used for patients with pain disorders and dystonia. The precise mechanism whereby BoNT-A controls pain remains elusive. Here, we studied how BoNT-A affects the expression of the transient receptor potential vanilloid subfamily member 1 (TRPV1), a ca
PMID 22820141